A prospective, multi-center, single-arm study, planned in 150 patients. The primary objective
of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging
(MRI)-guided transurethral ultrasound therapy system (TULSA-PRO) intended to ablate prostate
tissue of patients with localized, organ-confined prostate cancer.
Profound Medical Inc. has developed a novel technology called the MRI-guided transurethral
ultrasound therapy system (TULSA-PRO). The technology is developed for patients with organ
confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation
of prostate tissue.
The treatment is conducted within a MRI suite, which enables real-time temperature images of
the heated region to be acquired as the ultrasonic treatment is delivered. Using MRI
thermometry during treatment, dynamic temperature feedback control over the intensity of the
ultrasound beams and rotation of the Ultrasound Applicator can shape the pattern of thermal
coagulation accurately and precisely in the prostate gland.
It provides advantages of a non-invasive procedure with short treatment times.
1. Male, age 45 to 80 years
2. Biopsy-confirmed adenocarcinoma of the prostate. Biopsy (minimum 10 cores) obtained ≥
6 weeks and ≤ 6 months before treatment (or at the discretion of PI and approval by
3. Clinical stage ≤ T2b
4.1 Gleason score ≤ 3 + 4 (Part I only)
4.2 Gleason score 3+4 (Part II only) *now recruiting
5. PSA ≤ 15 ng/ml
6. Eligible for MRI [Form GCP-10131]
7. Eligible for general anesthesia (ASA category ≤ 3)
8. Prostate volume ≤ 90 cc, on Baseline MRI
9. Prostate size ≤ 5.0 cm in sagittal length, and ≤ 6.0 cm in axial diameter, on Baseline
10. Life expectancy ≥ 10 years
11. No calcifications in the planned ultrasound beam path, or at the discretion of the
investigator with approval from the Sponsor.
1. Evidence (including Baseline MRI and bone scan) of extracapsular extension, sphincter
involvement, seminal vesicle invasion, lymph node invasion or metastases
2. Suspected tumour on Baseline MRI within 3 mm of the prostatic urethra, or in the
prostate apex within 3 mm from the sphincter plane
3. Prior definitive treatment of prostate cancer
4. Prior transurethral resection of the prostate (TURP)
5. Use of 5-alpha reductase inhibitors (5-ARIs) or hormone therapy within 3 months prior
to the baseline visit. Baseline PSA must be established after a minimum of 3 months
following 5-ARIs discontinuation. Additionally, use of 5-ARIs is not permitted
following treatment during the study follow-up period.
6. Prostate calcifications > 1 cm in largest diameter, on Baseline Ultrasound
7. Cysts > 1 cm in largest diameter, on Baseline MRI
8. Bleeding disorder (INR > ULN and PTT > ULN)
9. Abnormal coagulation and current anticoagulant therapy. Patients whose anticoagulation
therapy can be temporarily reversed within 7 days prior to treatment are eligible.
Platelet inhibitors (ie: ASA) and heparin are not exclusion criteria.
10. Acute unresolved Urinary Tract Infection (UTI)
11. Interest in future fertility
12. History of any other malignancy other than skin cancer, or low grade bladder cancer
which has been completely resected, within the previous 2 years. Patients that have
had curative treatment of a previous malignancy and no recurrence of that malignancy
within the past 2 years will be allowed.
13. Patients with peripheral arterial disease with intermittent claudication or Leriches
14. Patients with diabetes who have evidence of complications from their diabetes, such as
end organ sequelae of diabetes or Hemoglobin A1c > 7%.
15. History of any major rectal or pelvic surgery or radiotherapy
16. History of ulcerative colitis or other chronic inflammatory conditions affecting
rectum (includes rectal fistula, anal stenosis)
17. Documented clinical prostatitis requiring therapy within 6 months prior to Treatment
18. History of urethral and bladder outlet disorders, including urethral stricture
disease, urethral diverticulae, bladder neck contracture, urethral fistulae, urethral
stenting, urethral sling, urethroplasty or chronic indwelling urethral catheter
19. Patients with artificial urinary sphincter or any penile implant
20. Severe neurogenic bladder
21. Untreated bladder stones
22. History of acute urinary retention within the last 12 months
23. Active untreated gross hematuria for any cause
24. Post Void Residual (PVR) bladder volume > 250 mL
25. Obstructing median lobe enlarged out of proportion to the rest of the prostate and
protruding significantly into the bladder, sometimes referred to as "ball valve"
median lobe, determined on Baseline MRI
26. Any prostate related investigational therapy within 6 months of Visit 1
27. History of Parkinson's disease or multiple sclerosis
28. History of drug abuse
29. Known infectious disease including HIV positivity or AIDS-related illness, HBV and HCV
30. Current unilateral or bilateral hydronephrosis
31. Allergy or contraindications to administration of the GI anti-spasmodic drug:
1. Patients in the USA: Glucagon
2. Patients in Canada and Europe: Buscopan (Hyoscine)
32. Contraindications to administration of gadolinium-based MRI contrast agent (e.g.
Magnevist), such as chronic, severe kidney disease, acute kidney injury, history of
Sickle Cell Disease, history of anemia, or intolerance/allergy to the contrast agent
33. Other severe, acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or study
drug administration, or may interfere with the interpretation of study results